uniQure to Participate in Multiple Upcoming Industry Conferences in June
June 02 2021 - 7:34AM
uniQure to Participate in Multiple Upcoming Industry Conferences in
June
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced its participation in the following upcoming
virtual investor and scientific conferences:
- Jefferies Virtual
Healthcare Conference, June 1 - 4, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Wednesday, June 2.
- A fireside chat with Matt Kapusta,
chief executive officer, will take place the same day from 8:30 to
8:55 a.m. ET. The live webcast of the fireside chat can be accessed
through the link displayed in the Investors & Newsroom section
of the uniQure website.
- European Hematology
Association (EHA) Virtual 2021, June 7 - 13, 2021
- uniQure will present two encore
presentations respectively highlighting 26-week clinical data from
the pivotal Phase 3 HOPE-B trial of the gene therapy etranacogene
dezaparvovec in patients with severe to moderately severe
hemophilia B.
- An oral presentation entitled “26
Week Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua
HFIX Variant; AMT-130) in Adults with Severe or Moderate-Severe
Hemophilia B Treated in the Phase 3 HOPE-B Clinical Trial” will be
available on June 11, 2021 at 9:00 a.m. ET.
- A poster presentation entitled
“Clinical Outcomes in Patients With and Without Pre-existing
Neutralizing Antibodies to the Vector: 6-Month Data from the Phase
3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec” will be
available on June 11, 2021 at 9:00 a.m. ET
- Goldman Sachs
42nd Annual Global Healthcare
Conference, June 8 - 11, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Wednesday, June 2.
- Matt Kapusta will participate in a
fireside chat the same day at 4:40 to 5:20 p.m. ET. The live
webcast of the fireside chat can be accessed through the link
displayed in the Investors & Newsroom section of the uniQure
website.
- uniQure’s Virtual Research
& Development Day, June 22, 2021
- uniQure will host a virtual
Research & Development Day on June 22, 2021 at 8:30 to 11:30
a.m. ET to highlight new investments in its expanding gene therapy
pipeline focusing on CNS and rare, liver-directed disorders, as
well as new advancements in platform technology and manufacturing.
Additional details can be accessed through the link displayed in
the Investors & Newsroom section of the uniQure
website.
- Raymond James Virtual Human
Health Innovation Conference, June 21 - 23, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Wednesday, June 23.
- Ricardo Dolmetsch, president of
research and development, will participate in a panel entitled
“Therapeutic Targets for Huntington’s Disease: We (Still) Down with
HTT?”, from 9:20 to 10:10 a.m. ET.
- A fireside chat with Matt Kapusta,
chief executive officer, will take place the same day from 9:10 to
9:35 a.m. ET. The live webcast of the fireside chat can be accessed
through the link displayed in the Investors & Newsroom section
of the uniQure website.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3
and other diseases. www.uniQure.com
uniQure Contacts:
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct:
339-970-7536 |
Direct:
617-306-9137 |
Direct:
339-970-7558 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Jul 2024 to Aug 2024
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Aug 2023 to Aug 2024